PHILADELPHIA--(BUSINESS WIRE)--Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, announced on June 4 that its affiliate company, Frontida BioPharm, Inc. (“Frontida”) has acquired certain assets from a wholly owned US subsidiary of Sun Pharma. The acquisition includes Sun Pharma’s oral solid dosage manufacturing facilities in Philadelphia, PA, and Aurora, IL and 15 related pharmaceutical products (the “Acquired Products”). Terms of the transaction were not disclosed. Frontida has been founded to provide Contract Manufacturing and Co-development services for Frontage’s large base of pharmaceutical industry clients and partners, and will utilize the facilities as its primary base of operations.
In connection with the transaction, Frontida has agreed to continue manufacturing certain products of Sun Pharma at these facilities on a contract basis and offer employment to all production, quality and administrative personnel at the sites. Additionally, Frontida will develop and manufacture the Acquired Products for distribution by commercial partners.
Frontida is offering co-development and commercialization services to pharmaceutical partners in collaboration with Frontage Laboratories’ research facilities in Exton, PA, and its affiliate’s research and development centers in Suzhou and Shanghai, China.
Commenting on the asset purchase, Dr. Song Li, CEO of Frontida BioPharm and Frontage Laboratories, said, "We are pleased to complete this transaction with Sun and partner with them in manufacturing some of their key products. The sites have experienced staff and state-of-the-art facilities and equipment that will serve as a foundation to Frontida’s launch of Contract Development and Manufacturing (“CDMO”) services. Frontida’s CDMO services will complement the high quality development services offered by Frontage Laboratories and provide our long-term clients a trusted partner for product manufacturing and commercial support.”
About Frontage / Frontida:
Frontage, a Tigermed company, a full service early-stage CRO with multiple locations in USA and China has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, it’s full service offerings include DMPK, bioanalysis using 60 LC-MS/MS instruments in support of preclinical and clinical studies, analytical testing, product development, and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health pharmaceutical companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Frontage has successfully enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets.
Frontida Biopharm, Inc., an affiliate of Frontage, is a Contract Development and Manufacturing Organization supporting biopharmaceutical companies in the scale-up and commercial manufacture of immediate and controlled release oral solid dose products. Frontida offers the capability to manufacture Highly Potent Active Ingredient (HPAI) products, Combination Products, as well as DEA schedules II – V products. Its patented Duragran® granulation process eliminates the need for traditional extrusion and compaction manufacturing steps, enhances drug loading, and creates better engineered and lower production-cost controlled release products. Together with Frontage’s CMC development services, Frontida offers Clinical Trial Materials manufacturing, serialized packaging, warehousing, and stability services as well. Frontida is working with Philadelphia and Pennsylvania officials to implement job training programs for skilled workers and support the region’s efforts to retain highly talented pharmaceutical professionals.